8 julio 2015
A phase II clinical trial shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition. Psoriasis is an immune-mediated disease that causes itchy, dry and red skin. It also increases a patient’s risk for depression, heart disease and diabetes, among other conditions. The disease affects nearly 3 percent of the world’s population.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/eFothI66tN8/150708181711.htm
